A Study of the Potential Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study to Evaluate the Effect of Multiple Doses of Quinidine Sulfate, a P-glycoprotein (P-gp) Inhibitor, on the Pharmacokinetics of Nalbuphine Extended-Release Tablets in Healthy Adult Subjects
The primary purpose of this study is to evaluate the effect of quinidine sulfate on the pharmacokinetics (PK) of NAL ER in healthy participants.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Aryany Sanchez
- Phone Number: 203-304-2499
- Email: aryany.sanchez@trevitx.com
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33172
- Recruiting
- Clinical Pharmacology of Miami, LLC
-
Contact:
- Veronica Gomez, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kilogram per meter square (kg/m^2) at screening.
- Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or electrocardiograms (ECGs), as deemed by the principal investigator (PI) or designee.
Exclusion Criteria:
- History of any diagnosed moderate or severe substance use disorder, other than tobacco use disorder, or a history of or current regular excessive consumption of alcohol.
- Positive urine drug or alcohol results.
- Smoker who has smoked or used nicotine containing products within the last 3 months.
- Clinically significant hypokalemia or hypomagnesemia at the screening visit.
- History of prolonged QT syndrome.
- Abnormal liver tests at screening.
- Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
- Abnormal estimated glomerular filtration rate (eGFR).
Note: Other inclusion/exclusion criteria mentioned in the protocol may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: NAL ER and Quinidine
Participants will receive NAL ER followed by NAL ER co-administered with quinidine. |
Oral tablets
Other Names:
Oral tablets |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum Plasma Concentration (Cmax) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
|
Time to Reach Maximum Observed Concentration (Tmax) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
|
Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUC0-Tlast) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
|
Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
|
Apparent Terminal Rate Constant (λz) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
|
Apparent Terminal Half-Life (t1/2) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time Frame: Up to Day 19
|
Up to Day 19
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Chief Development Officer, Trevi Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Alkaloids
- Polycyclic Aromatic Hydrocarbons
- Polycyclic Compounds
- Heterocyclic Compounds, 4 or More Rings
- Quinolines
- Morphinans
- Opiate Alkaloids
- Heterocyclic Compounds, Bridged-Ring
- Phenanthrenes
- Quinuclidines
- Cinchona Alkaloids
- Nalbuphine
- Quinidine
Other Study ID Numbers
Other Study ID Numbers
- NAL00-110
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.